The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development

Original title: The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development.

Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented.

By Zhang, Eckmann, Miao +2Science (New York, N.Y.)Oct 22, 2026

Score█████░░░░░4.9

Key numbers

48% more likely to reach
32% fewer adverse events

Caveats

Not randomized: its findings are associations.

VerdictWorth a reader's time today.

Read the original

Abstract

Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development. We demonstrate its utility at three drug-development decision points. First, more than 37,000 agents annotated outcomes from 55,984 trials and found that drugs targeting cell type-specific genes were 48% more likely to reach market with 32% fewer adverse events. Second, it integrated multimodal evidence to propose a therapeutic strategy in lung cancer. Third, it analyzed a terminated ulcerative colitis trial and inferred potential mechanisms of failure. These results demonstrate that human-guided multi-agent systems can conduct transparent, multiscale analyses to inform therapeutic-development decisions.

Harrison G Zhang, Peter Eckmann, Jiacheng Miao, Andrew B Mahon, James Zou

The editor's rubric

Heuristic review

Leverage3 / 5: A method or resource many groups across the field will adopt within a year.; 10% of this desk’s rubric
Magnitude3 / 5: Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.; 20% of this desk’s rubric
Evidence3 / 5: Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.; 32% of this desk’s rubric
Novelty3 / 5: A genuinely new approach to an open problem.; 8% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 5% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	███░░ 3	10%	A method or resource many groups across the field will adopt within a year.
Magnitude	███░░ 3	20%	Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
Evidence	███░░ 3	32%	Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.
Novelty	███░░ 3	8%	A genuinely new approach to an open problem.
Trajectory	██░░░ 2	5%	Some room to improve with obvious engineering.
Stakes	███░░ 3	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose, we report); novelty (discovery); scale (scalable); stakes (major disease, prevention or cure). Red flags: not randomized.

How the score was computed

rank-2026-10-18

Score█████░░░░░4.9

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 5.9 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 4.8 / 10; Shrunk toward the desk prior by editor confidence (42%).
Attention: 18%; Citations, upvotes, points, mentions.
Freshness: 85%; Half-life decay since publication.

Citations5 (reference 20, via openalex, Oct 24, 2026, 06:17 UTC)

The record

Reviewed by heuristic-v7 on Oct 24, 2026, 06:17 UTC. Paper type: clinical.
Categories: Journal Article, Humans, Lung Neoplasms, Colitis, Ulcerative, Biotechnology, Artificial Intelligence, Clinical Trials as Topic, Drug Discovery, Drug Development
TOP, No.5 in the Medicine edition of October 24, 2026.